Startseite>>Signaling Pathways>> Proteases>> HIV Integrase>>(±)-BI-D

(±)-BI-D

Katalog-Nr.GC34961

(±)-BI-D ist ein potenter ALLINI (ein allosterischer IN-Inhibitor), der Integrase an der LEDGF/p75-Bindungsstelle bindet.

Products are for research use only. Not for human use. We do not sell to patients.

(±)-BI-D Chemische Struktur

Cas No.: 1416258-16-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
289,00 $
Auf Lager
2mg
216,00 $
Auf Lager
5mg
324,00 $
Auf Lager
10mg
464,00 $
Auf Lager
50mg
1.391,00 $
Auf Lager
100mg
1.947,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.IC50 value: 2.4-2.9 μM(HIV-Luc infection of WT and Hdgfrp2 KO cells) [1]Target: integrase inhibitorin vitro: Approximately 2.4-2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160-200 nM, in Psip1 and double-KO cells [1].

[1]. Wang H, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012 Dec;40(22):115 [2]. Fader LD, et al. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. ACS Med Chem Lett. 2014 Apr 16;5(6):711-6.

Bewertungen

Review for (±)-BI-D

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (±)-BI-D

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.